The revised indication statement is based on extensive safety and effectiveness data from retrospective studies as well as three prospective clinical trials.

"SI-BONE’s strong clinical evidence demonstrating consistently positive results across multiple clinical trials makes it much easier for our regulatory team and the Agency to process our regulatory applications, such as this premarket notification to update the indication statement," said Roxanne Dubois, Vice President of Quality and Regulatory Affairs at SI-BONE, Inc.

The iFuse ImplantSM has a unique patented triangular shape that provides 31 times the rotational resistance of a screw.

It is the only commercially available SI joint fusion device with published clinical evidence, including three large multicenter prospective studies, that demonstrates safety and effectiveness. Currently, there are more than 40 peer reviewed publications supporting positive clinical outcomes, safety, biomechanics, and economic benefits of iFuse.

"This is a significant milestone in the evolution of the treatment of SI joint dysfunction and clearly sets iFuse apart from any other surgical treatment option," said Jeffrey Dunn, President and CEO of SI-BONE.

"No other surgical treatment option for SI joint dysfunction is supported by prospective data and now with over 21,000 procedures performed worldwide, iFuse is clearly the surgical treatment of choice for SI joint dysfunction due to SI joint disruption or degenerative sacroiliitis."

SI-BONE, Inc. (San Jose, California) is a leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders.

The company develops, manufactures and markets minimally invasive products for the SI joint. SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010.